Allogene Therapeutics (ALLO) Income towards Parent Company (2018 - 2026)

Allogene Therapeutics has reported Income towards Parent Company for 9 years, with the latest figure at -$145.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 96.88% year-over-year to -$145.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$337.7 million (up 16.0% YoY) and the FY2025 annual result came in at -$190.9 million, up 25.9% from the prior year.
• Income towards Parent Company slipped to -$145.2 million in Q1 2026 per ALLO's latest filing, from -$50.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$50.9 million in Q4 2025 and troughed at -$224.9 million in Q3 2022.
• A 5-year average of -$100.6 million and a median of -$81.5 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company slumped 3379.13% in 2022, then soared 60.27% in 2025.
• Over 5 years, Income towards Parent Company stood at -$100.5 million in 2022, then rose by 27.55% to -$72.8 million in 2023, then increased by 21.0% to -$57.5 million in 2024, then advanced by 11.58% to -$50.9 million in 2025, then slumped by 185.38% to -$145.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$145.2 million, -$50.9 million, and -$65.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.